Patents Examined by John Lucas
  • Patent number: 6077685
    Abstract: A novel tumor suppressor protein, merlin, is described, including DNA sequences encoding merlin, and recombinant vectors and hosts capable of expressing merlin. Method for the diagnosis and treatment of merlin-associated tumors, and for the diagnosis and treatment of the disease neurofibromatosis 2 (NF2) are also provided.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: June 20, 2000
    Assignee: The General Hospital Corporation
    Inventors: James A. Trofatter, Mia M. MacCollin, James F. Gusella
  • Patent number: 5879911
    Abstract: A novel protein which is glycoprotein with 120,000 molecular weight and is expressed on T lymphoblastic lymphoma and leukemia cells, is useful in the diagnosis of T lymphoblastic lymphoma and leukemia.
    Type: Grant
    Filed: January 15, 1997
    Date of Patent: March 9, 1999
    Assignee: Seong Hoe Park
    Inventors: Seong Hoe Park, Young Mee Bae
  • Patent number: 5866123
    Abstract: The present invention provides a novel gene encoding a cationic amino acid transporter protein. The present invention also provides antibodies specific for the cationic amino acid transporter protein. Further, the present invention provides methods of treating a disease characterized by undesirable levels of nitric oxide and methods of inhibiting cationic amino acid transport.
    Type: Grant
    Filed: January 26, 1994
    Date of Patent: February 2, 1999
    Assignee: Research Development Foundation
    Inventor: Carol L. Mac Leod
  • Patent number: 5856456
    Abstract: The invention is directed to a novel peptide linker useful for connecting polypeptide constituents into a novel linked fusion polypeptide. The peptide linker of the invention provides greater stability and is less susceptible to aggregation than previously known peptide linkers. The peptide linker of the invention may be up to about 50 amino acids in length and contains at least one occurrence of a charged amino acid followed by a proline. When used for making a single chain Fv (sFv), the peptide linker is preferably from 18 to about 30 amino acids in length. A preferred embodiment of the peptide linker of the invention comprises the sequence:GSTSGSGXPGSGEGSTKG (SEQ. ID NO 1),where X is a charged amino acid, preferably lysine or arginine. Methods of making linked fusion polypeptides using the peptide linker of the invention are claimed. DNA molecules encoding such linked fusion polypeptides, and methods of producing such linked fusion polypeptides from these DNA molecules are also claimed.
    Type: Grant
    Filed: April 7, 1994
    Date of Patent: January 5, 1999
    Assignee: Enzon, Inc.
    Inventors: Marc D. Whitlow, David R. Filpula
  • Patent number: 5846739
    Abstract: A method of determining the proliferative status of a carcinoma is disclosed. One obtains a patient sample and then quantitatively analyzes the sample for NGAL gene expression product. The amount of NGAL expression product is compared with a standard curve to determine the S-phase value. The sample can be breast tissue or breast fluid aspirate. Alternatively, blood can by analyzed for this marker to diagnose metastasis.
    Type: Grant
    Filed: January 6, 1997
    Date of Patent: December 8, 1998
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Michael N. Gould, Steven P. Stoesz
  • Patent number: 5821238
    Abstract: This invention relates to the production and use of recombinant Pseudomonas-derived toxins modified to increase their toxicity and potency in therapy. More particularly, the invention relates to certain deletions in domain II of the amino acid sequence of Pseudomonas exotoxin the domain which relates to the toxin's natural proteolytic processing.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: October 13, 1998
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Ira H. Pastan, David J. Fitzgerald
  • Patent number: 5821123
    Abstract: Methods are described for identifying the amino acid residues of an antibody variable domain which may be modified without diminishing the native affinity of the domain for antigen while reducing its immunogenicity with respect to a heterologous species and for preparing so modified antibody variable domains which are useful for administration to heterologous species. Antibody variable regions prepared by the methods of the invention are also described.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: October 13, 1998
    Assignee: XOMA Corporation
    Inventor: Gary M. Studnicka
  • Patent number: 5811097
    Abstract: T cell activation in response to antigen is increased by the administration of binding agents that block CTLA-4 signaling. When CTLA-4 signaling is thus blocked, the T cell response to antigen is released from inhibition. Such an enhanced response is useful for the treatment of tumors, chronic viral infections, and as an adjuvant during immunization.
    Type: Grant
    Filed: May 8, 1996
    Date of Patent: September 22, 1998
    Assignee: The Regents of the University of California
    Inventors: James Patrick Allison, Dana R. Leach, Matthew F. Krummel
  • Patent number: 5808033
    Abstract: The present invention discloses novel chimeric monoclonal antibodies directed against human carcinoembryonic antigen, having antigen-specific variable regions. DNA constructs for the light and heavy chain variable regions comprising the novel antibodies of the invention are also disclosed. Eukaryotic host cells capable of expression of the chimeric antibodies and comprising the novel chimeric antibody-encoding DNA constructs are also described.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: September 15, 1998
    Assignee: The Dow Chemical Company
    Inventors: Brian B. Gourlie, Mark W. Rixon, Peter S. Mezes
  • Patent number: 5807734
    Abstract: An anti-CD2 monoclonal antibody according to the present invention can be: (1) a chimeric monoclonal antibody CD2 SFv-Ig produced by expression of the construct cloned in recombinant Escherichia coli culture ATCC No. 69277; (2) a monoclonal antibody having complementarity-determining regions identical with those of CD2 SFv-Ig; or (3) a monoclonal antibody competing with CD2 SFv-Ig for binding to CD2 antigen at least about 80% as effectively on a molar basis as CD2 SFv-Ig. Anti-CD2 monoclonal antibodies according to the present invention, as well as other antibodies that can modulate the interactions between T lymphocytes and monocytes, can be used to inhibit the production of HIV-1 by HIV-1-infected T cells in HIV-1-infected patients. In another use, T cells treated in vitro can be reinfused into AIDS patients to increase the proportion of functional, non-HIV-1-producing T cells in the patient.
    Type: Grant
    Filed: May 31, 1995
    Date of Patent: September 15, 1998
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michael L. Diegel, Peter S. Linsley, Lisa K. Gilliland, Patricia A. Moran, Joyce M. Zarling, Jeffrey A. Ledbetter
  • Patent number: 5801145
    Abstract: A method for the selective purging ex vivo of CD77 positive cells from bone marrow prior to autologous transplantation is described. The method involves treating the bone marrow with shiga toxin or shiga-like toxin-1 to kill CD77.sup.+ cells or to remove them by affinity chromatography. The toxin selectively binds to CD77.sup.+ cells and not to other bone marrow cells. The method offers a means for curing non-Hodgkin's lymphomas.
    Type: Grant
    Filed: February 9, 1996
    Date of Patent: September 1, 1998
    Assignee: Ontario Cancer Institute
    Inventor: Jean Gariepy
  • Patent number: 5795572
    Abstract: An anti-CD2 monoclonal antibody according to the present invention can be: (1) a chimeric monoclonal antibody CD2 SFv-Ig produced by expression of the construct cloned in recombinant Escherichia coli culture ATCC No. 69277; (2) a monoclonal antibody having complementarity-determining regions identical with those of CD2 SFv-Ig; or (3) a monoclonal antibody competing with CD2 SFv-Ig for binding to CD2 antigen at least about 80% as effectively on a molar basis as CD2 SFv-Ig. Anti-CD2 monoclonal antibodies according to the present invention, as well as other antibodies that can modulate the interactions between T lymphocytes and monocytes, can be used to inhibit the production of HIV-1 by HIV-1-infected T cells in HIV-1-infected patients. In another use, T cells treated in vitro can be reinfused into AIDS patients to increase the proportion of functional, non-HIV-1-producing T cells in the patient.
    Type: Grant
    Filed: May 25, 1993
    Date of Patent: August 18, 1998
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michael L. Diegel, Peter S. Linsley, Lisa K. Gilliland, Patricia A. Moran, Joyce M. Zarling, Jeffrey A. Ledbetter
  • Patent number: 5792458
    Abstract: A potent and specific immunotoxin is prepared by coupling an inactivated diphtheria toxin to a binding moiety such as a monoclonal antibody or transferrin. The immunotoxins are specific for human tumors and leukemias and are indistinguishable in cell toxicity from that of the native toxin linked to the binding domain without the toxicity to other cells. The immunotoxin is useful in treating graft versus host disease as well as selectively killing tumor cells, such as medulloblastoma and glioblastoma cells.
    Type: Grant
    Filed: October 17, 1994
    Date of Patent: August 11, 1998
    Assignees: The United States of America as represented by the Department of Health and Human Services, Cetus Corporation
    Inventors: Virginia G. Johnson, Larry Greenfield, Richard J. Youle, Walter Laird
  • Patent number: 5776895
    Abstract: The present invention is directed to products containing G-CSF and a TNF binding protein and compositions of G-CSF and TNF-BP, and methods of treating and/or preventing septic shock by administering the products and compositions of the invention.
    Type: Grant
    Filed: January 23, 1995
    Date of Patent: July 7, 1998
    Assignee: Hoffman-La Roche Inc.
    Inventors: Gottfried Alber, Peter Angehrn
  • Patent number: 5770196
    Abstract: Methods are described for identifying the amino acid residues of an antibody variable domain which may be modified without diminishing the native affinity of the domain for antigen while reducing its immunogenicity with respect to a heterologous species and for preparing so modified antibody variable domains which are useful for administration to heterologous species. Antibody variable regions prepared by the methods of the invention are also described.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: June 23, 1998
    Assignee: XOMA Corporation
    Inventor: Gary M. Studnicka
  • Patent number: 5766886
    Abstract: Methods are described for identifying the amino acid residues of an antibody variable domain which may be modified without diminishing the native affinity of the domain for antigen while reducing its immunogenicity with respect to a heterologous species and for preparing so modified antibody variable domains which are useful for administration to heterologous species. Antibody variable regions prepared by the methods of the invention are also described.
    Type: Grant
    Filed: August 13, 1993
    Date of Patent: June 16, 1998
    Assignee: Xoma Corporation
    Inventors: Gary M. Studnicka, Roger G. Little, II, Dianne M. Fishwild, Fred R. Kohn
  • Patent number: 5763195
    Abstract: The complete amino acid and nucleotide sequence for adenylate cyclase stimulating factor is provided, thereby facilitating the synthesis of ACSF in recombinant cell culture. ACSF amino acid sequence variants and ACSF antibodies are provided which are useful in the treatment of humoral hypercalcemia of malignancy or in immunoassays for ACSF. In particular, antibodies capable of binding only the C-terminal domains of ACSF are useful in immunoassays for ACSF which avoid interference by parathyroid hormone. Also provided are novel polypeptides selected from the group of the ACSF basic peptide, the ACSF C-terminal peptide, or the ACSF domain containing both of the basic and C-terminal peptides.
    Type: Grant
    Filed: April 20, 1995
    Date of Patent: June 9, 1998
    Assignees: Genentech, Inc., University of Melbourne
    Inventors: William I. Wood, Thomas John Martin, Larry John Suva
  • Patent number: 5753225
    Abstract: The use and production of immunoglobulins which activate trk receptors and imitate effects of neurotrophins are provided. Immunoglobulins which block trk receptor activation and methods of use are also provided.
    Type: Grant
    Filed: December 3, 1993
    Date of Patent: May 19, 1998
    Assignee: The Regents of the University of California
    Inventors: Douglas O. Clary, Gisela Weskamp, Leeann R. Austin, Louis F. Reichardt
  • Patent number: 5750503
    Abstract: The present invention is directed to products containing G-CSF and a TNF binding protein and compositions of G-CSF and TNF-BP, and methods of treating and/or preventing septic shock by administering the products and compositions of the invention.
    Type: Grant
    Filed: May 5, 1995
    Date of Patent: May 12, 1998
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Gottfried Alber, Peter Angehrn
  • Patent number: 5747033
    Abstract: Novel ligands that bind Eph family receptors are identified, and methods for making the soluble ligands in biologically active form are described. cDNA clones encoding these novel proteins enable production of the recombinant proteins, which are useful to support neuronal and other receptor-bearing cell populations.
    Type: Grant
    Filed: September 1, 1994
    Date of Patent: May 5, 1998
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Samuel Davis, Nicholas W. Gale, Thomas H. Aldrich, Peter C. Maisonpierre, Mitchell Goldfarb, George D. Yancopoulos